chronic myeloid
Molecular-cytogenetic variant in chronic myeloid leukemia
... Chronic myeloid leukemia (CML) was the first neoplastic disease to be linked to a genetic abnormality and is the best studied molecular model of leukemia. The increased and cumulative knowledge of this ...
2
Pancytopenia during tyrosine kinase inhibitor treatment–coexistence of chronic myeloid leukemia and visceral leishmaniasis : a case report
... with chronic myeloid leukemia treated with imatinib who developed significant pancytopenia, leading to discontinuation of ...of chronic myeloid leukemia and numerous Leishmania amastigotes ...
4
An uneventful pregnancy and delivery in a patient with chronic myeloid leukemia
... of chronic myeloid leukemia and pregnancy is uncommon and projected to be one in 75000-100000 pregnancies ...as chronic myeloid leukemia in chronic ...for chronic myeloid ...
2
Granulocytic sarcoma presented as a reactivation of chronic myeloid leukemia after allogenic marrow transplantation
... a chronic myeloid leukemia (CML) patient submitted to allogenic bone marrow transplantation, who had probably never entered complete ...a myeloid Ph1+ blastic crisis that was unsuccessfully treated ...
3
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients.
... Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy characterized by the t(9;22) chromosomal translocation that generates the BCR/ABL oncogene ...
13
BioCode gold-nanobeacon for the detection of fusion transcripts causing chronic myeloid leukemia
... The effective sequence selectivity of the BioCode Au- nanobeacon was demonstrated using the most com- mon BCR-ABL fusion transcripts (e13a2 and e14a2) as a model. The formation of the BCR-ABL fusion sequences is ...
9
Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.
... Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by the t (9; 22) chromosomal ...in myeloid proliferation ...in chronic phase (CP) patients who develop ...
9
Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.
... including myeloid derived suppressor cells (MDSCs), able to inhibit T cells ...in chronic myeloid leukemia (CML) patients at diagnosis that decreased to normal levels after imatinib ...
10
Detection of mutator phenotype in Brazilian patients with acute and chronic myeloid leukemia
... The multisteps of tumorigenesis involve the classic chromosomal instability and the mutator phenotype pathways featured by a predisposition to acquire mutations in tumor suppressor genes and oncogenes. Expansion and ...
6
Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia
... with chronic myeloid leukemia were selected to start this new model of ...with chronic myeloid leukemia and treated with tyronsine kinase inhibitors, 42 were selected due to the frequency of ...
10
Development of a liposomal formulation for peptide delivery to serve as vaccine against chronic myeloid leukemia
... Chronic myeloid leukemia (CML) is a malignant disorder that originates in a single abnormal hematopoietic stem ...a chronic phase (CP) that can last for 3 to 5 years, and if untreated, it progresses ...
159
Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis
... 84 chronic myeloid leukemia (CML) patients and 65 healthy controls; and vascular endothelial growth factor (VEGF) by quantitative real- time PCR in 50 CML patients and 32 healthy ...in chronic- or ...
6
BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.
... Figure 1. BCR-ABL downregulates PTEN expression. A) Left panel: evaluation of PTEN levels of expression in BCR-ABL-pcDNA3.1 transfected NIH3T3. Right panel: quantification of PTEN levels. B) PTEN mRNA levels in BCR-ABL ...
4
ANALYSIS OF mRNA TRANSCRIPTS IN CHRONIC MYELOID LEUKEMIA PATIENTS
... The nature of BCR/ABL hybrid mRNA was analyzed by RT-PCR in cells from 33 patients (22 males, 11 females) with chronic myeloid leukemia (CML). b3a2 mRNA was found in 14 cases, whereas 13 patients had b2a2 ...
6
Gold nanoparticles for nanotheranostics in leukemia – Addressing Chronic Myeloid Leukemia
... diagnose chronic myeloid leukemia using its genetic marker, BCR-ABL1 fusion transcript; iii) Total RNA extracted from white blood cells is then mixed with Au-nanoprobes and heated to promote ...
220
Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.
... Before the era of tyrosine kinase inhibitors (TKIs), interferon-alpha (IFN-a) was the treatment of choice in chronic myeloid leukemia (CML). Curiously, some IFN-a treated patients were able to discontinue ...
12
Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.
... In vitro, IM/BOR and IM/PSI exhibit an enhanced inhibition of long-term colony forming activity and short-term cell growth of CD34 + cells from CML patients at CP or BC (Figure 3), cause[r] ...
16
Chronic myeloid leukemia (CML): prognostic factors and survival analysis
... January 1993. The follow-up period varied from 1 to 184 m onths. There were 7 (15.5 percent) patients with a follow-up of less than 1 year, and 3 (6.7 percent) with less than 6 m onths. The diagnosis of CM L was based on ...
8
Clinics vol.70 número8
... 11. Machado MP, Tomaz JP, Lorand-Metze I, Souza CA De, Vigorito AC, Delamain MT, et al. Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase – ...
6
Rev. Bras. Hematol. Hemoter. vol.35 número2
... 3. Rezende VM, Rivellis AJ, Gomes MM, Dörr FA, Novaes MM, Nardinelli L, et al. Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a ...
2